Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine

Pfizer (NYSE:PFE) is taking on significant risk in a race to provide the world with a coronavirus vaccine. Pfizer is outsourcing the production of its own branded medicines to contract manufacturers such as Catalent (NYSE:CTLT) to make room for the production of, BNT162, an experimental SARS-CoV-2 vaccine the big pharma is developing in partnership with BioNTech (NASDAQ:BNTX).